30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Invariant NKT cells are resistant to circulating CD15 + myeloid‐derived suppressor cells in patients with head and neck cancer

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Myeloid‐derived suppressor cells (MDSC) are a heterogeneous population of immature and progenitor myeloid cells with an immunosuppressive role in various types of cancer, including head and neck squamous cell carcinoma (HNSCC). However, the effect on the host immune system, especially on invariant NKT (iNKT) cells with potent anti‐tumor activity, remains unclear. In this study, we investigated the effects of circulating MDSC subsets on the peripheral lymphocytes of patients with head and neck tumors. A significant accumulation of CD15 + granulocytic MDSC (G‐MDSC) and CD14 + monocytic MDSC (M‐MDSC) was demonstrated in HNSCC patients. The percentage of G‐MDSC showed an inverse correlation with the percentage of T cells in the peripheral blood. The increased G‐MDSC was significantly associated with advanced clinical stage and poor prognosis of HNSCC patients. The proliferation and viability of T cells were suppressed by CD15 + cells, and the suppression was reversed by adding the hydrogen peroxide scavenger catalase. However, iNKT cell activation upon α‐galactosylceramide (αGalCer) stimulation was not affected by the presence or absence of CD15 + G‐MDSC. These results indicate that increased G‐MDSC negatively affects peripheral T cell immunity, but not iNKT cells, in HNSCC patients, and that T cells are more sensitive to hydrogen peroxide produced by G‐MDSC than iNKT cells. Cancer immunotherapy designed to enhance the antitumor activity of iNKT cells by stimulation with αGalCer may remain effective in the presence of G‐MDSC.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          Myeloid-derived suppressor cells: linking inflammation and cancer.

          Many cancer immunotherapies developed in experimental animals have been tested in clinical trials. Although some have shown modest clinical effects, most have not been effective. Recent studies have identified myeloid-origin cells that are potent suppressors of tumor immunity and therefore a significant impediment to cancer immunotherapy. "Myeloid-derived suppressor cells" (MDSC) accumulate in the blood, lymph nodes, and bone marrow and at tumor sites in most patients and experimental animals with cancer and inhibit both adaptive and innate immunity. MDSC are induced by tumor-secreted and host-secreted factors, many of which are proinflammatory molecules. The induction of MDSC by proinflammatory mediators led to the hypothesis that inflammation promotes the accumulation of MDSC that down-regulate immune surveillance and antitumor immunity, thereby facilitating tumor growth. This article reviews the characterization and suppressive mechanisms used by MDSC to block tumor immunity and describes the mechanisms by which inflammation promotes tumor progression through the induction of MDSC.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.

            Natural killer T (NKT) lymphocytes express an invariant T cell antigen receptor (TCR) encoded by the Valpha14 and Jalpha281 gene segments. A glycosylceramide-containing alpha-anomeric sugar with a longer fatty acyl chain (C26) and sphingosine base (C18) was identified as a ligand for this TCR. Glycosylceramide-mediated proliferative responses of Valpha14 NKT cells were abrogated by treatment with chloroquine-concanamycin A or by monoclonal antibodies against CD1d/Vbeta8, CD40/CD40L, or B7/CTLA-4/CD28, but not by interference with the function of a transporter-associated protein. Thus, this lymphocyte shares distinct recognition systems with either T or NK cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mouse CD1-specific NK1 T cells: development, specificity, and function.

              NK1 T cells are a specialized population of alpha/beta T cells that coexpress receptors of the NK lineage and have the unique potential to very rapidly secrete large amounts of cytokines, providing early help for effector cells and regulating the Th1 or Th2 differentiation of some immune responses. NK1 T cells express a restricted TCR repertoire made of an invariant TCR alpha chain, V alpha 14-J alpha 281, associated with polyclonal V beta 8, V beta 7, and V beta 2 TCR beta chains. NK1 T cells recognize the products of the conserved family of MHC class I-like CD1 genes, apparently in the absence of foreign antigens. Thus, this novel regulatory pathway, which straddles the innate and the adaptive immune systems, is unique in that its activation may not require associative recognition of antigen. Here, we review the specificity and function of mouse NK1 T cells, and we discuss the relationship of this lineage to mainstream T cells and NK cells.
                Bookmark

                Author and article information

                Journal
                Cancer Sci
                Cancer Sci
                10.1111/(ISSN)1349-7006
                CAS
                Cancer Science
                John Wiley and Sons Inc. (Hoboken )
                1347-9032
                1349-7006
                13 February 2016
                March 2016
                : 107
                : 3 ( doiID: 10.1111/cas.2016.107.issue-3 )
                : 207-216
                Affiliations
                [ 1 ] Department of Otorhinolaryngology, Head and Neck SurgeryGraduate School of Medicine, Chiba University ChibaJapan
                [ 2 ] Department of ImmunologyGraduate School of Medicine, Chiba University ChibaJapan
                [ 3 ] Department of Medical ImmunologyGraduate School of Medicine, Chiba University ChibaJapan
                Author notes
                [*] [* ] Correspondence

                Daiju Sakurai, Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, 1‐8‐1 Inohana, Chuo‐ku, Chiba 260‐8670, Japan.

                Tel: +81‐43‐226‐2137; Fax: +81‐43‐227‐3442;

                E‐mail: sakuraidai@ 123456faculty.chiba-u.jp

                [†]

                Atsushi Horinaka and Daiju Sakurai contributed equally to this study.

                Article
                CAS12866
                10.1111/cas.12866
                4814259
                26679292
                97ee880c-e816-4969-b55d-1a27eb1647e0
                © 2015 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 17 August 2015
                : 24 November 2015
                : 15 December 2015
                Page count
                Pages: 10
                Funding
                Funded by: Japan Society for the Promotion of Science
                Award ID: 22791569
                Award ID: 24592589
                Categories
                Original Article
                Original Articles
                Basic and Clinical Immunology
                Custom metadata
                2.0
                cas12866
                March 2016
                Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.5 mode:remove_FC converted:30.03.2016

                Oncology & Radiotherapy
                head and neck cancer,hydrogen peroxide,immune suppression,invariant nkt cell,squamous cell carcinoma

                Comments

                Comment on this article